Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (Gej) adenocarcinoma PR Newswire (Press Release) 00:37 Tue, 25 Aug
Is Astellas Pharma’s First-Quarter 2026 Profit Surge Altering The Investment Case For Astellas Pharma (TSE:4503)? Simply Wall St 20:39 Sat, 15 Aug
Putting innovation—and patients—in focus: A conversation with Astellas Pharma CEO Naoki Okamura The McKinsey Quarterly 15:35 Thu, 13 Aug
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas FiercePharma 16:49 Wed, 12 Aug
